Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study

SS Runchey[1,2], MN Pollak[3], LM Valsta[4], GD Coronado[5], Y Schwarz[2], KL Breymeyer[2], C Wang[2], C-Y Wang[2], JW Lampe[2,6] and ML Neuhouser[2,6]

BACKGROUND/OBJECTIVES: The effect of a low glycemic load (GL) diet on insulin-like growth factor-1 (IGF-1) concentration is still unknown but may contribute to lower chronic disease risk. We aimed to assess the impact of GL on concentrations of IGF-1 and IGF-binding protein-3 (IGFBP-3).

SUBJECTS/METHODS: We conducted a randomized, controlled crossover feeding trial in 84 overweight obese and normal weight healthy individuals using two 28-day weight-maintaining high- and low-GL diets. Measures were fasting and post-prandial concentrations of insulin, glucose, IGF-1 and IGFBP-3. In all 80 participants completed the study and 20 participants completed post-prandial testing by consuming a test breakfast at the end of each feeding period. We used paired *t*-tests for diet component and linear mixed models for biomarker analyses.

RESULTS: The 28-day low-GL diet led to 4% lower fasting concentrations of IGF-1 (10.6 ng/ml, $P = 0.04$) and a 4% lower ratio of IGF-1/IGFBP-3 (0.24, $P = 0.01$) compared with the high-GL diet. The low-GL test breakfast led to 43% and 27% lower mean post-prandial glucose and insulin responses, respectively; mean incremental areas under the curve for glucose and insulin, respectively, were 64.3 ± 21.8 (mmol/l/240 min; $P < 0.01$) and 2253 ± 539 (μU/ml/240 min; $P < 0.01$) lower following the low- compared with the high-GL test meal. There was no effect of GL on mean homeostasis model assessment for insulin resistance or on mean integrated post-prandial concentrations of glucose-adjusted insulin, IGF-1 or IGFBP-3. We did not observe modification of the dietary effect by adiposity.

CONCLUSIONS: Low-GL diets resulted in 43% and 27% lower post-prandial responses of glucose and insulin, respectively, and modestly lower fasting IGF-1 concentrations. Further intervention studies are needed to weigh the impact of dietary GL on risk for chronic disease.

Keywords: adiposity; glycemic index; insulin resistance; insulin-like growth factor-1; insulin-like growth factor-binding protein 3; randomized controlled trial

INTRODUCTION

Dietary intervention studies have shown detrimental metabolic effects of high-glycemic load (GL) diets, including higher post-prandial glucose and insulin concentrations, less desirable lipid profiles[1] and propensity for obesity.[2] Glycemic index (GI) is the numerical classification of a particular food's blood glucose-raising effect.[3] The term 'glycemic load' has been used to denote meal- or overall diet-related glycemic effect.[4–6] GL is defined as the product of grams of carbohydrate × GI/100[4] and accounts for both the quantity and quality of dietary carbohydrate. The potentially detrimental metabolic effects are reflected in some of the epidemiological studies that support an association between high-GL diets and increased risk for type 2 diabetes.[5–7]

Chronic hyperinsulinemia, as a result of a high GL (or GI) diet, has also been proposed as a risk factor for several types of cancers, though not all studies point toward this risk.[8,9] High insulin-like growth factor-1 (IGF-1) concentration, like hyperinsulinemia, may also contribute to increased risk for some types of cancer;[10] however, whether insulin and IGF-1 act through similar mechanisms is unclear. Concentrations of a major binding protein for IGF-1, IGF-binding protein 3 (IGFBP-3), affect the bio-availability of IGF-1 (indicated by the molar ratio of IGF-1/IGFBP-3)[11] and may also be independently associated with cancer risk.[12]

Contrary to a proposed cancer protective effect of low IGF-1 concentration, epidemiological studies suggest a lower ratio of IGF-1/IGFBP-3 is associated with components of the metabolic

[1]Division of Endocrinology, Metabolism and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA; [2]Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [3]Jewish General Hospital, Department of Oncology, McGill University, Montreal, Canada, USA; [4]Finnish National Institute for Health and Welfare, Nutrition Unit and European Food Safety Authority (EFSA), Dietary and Chemical Monitoring Unit, Parma, Italy; [5]Center for Health Research, Kaiser Permanente, Portland, OR, USA and [6]Department of Epidemiology and Interdisciplinary Graduate Program in Nutritional Sciences, University of Washington, Seattle, WA, USA. Correspondence: Dr ML Neuhouser, Fred Hutchinson Cancer Research Center, PO Box 19024, M4-B402, Seattle, WA 98109, USA.
E-mail: mneuhous@fhcrc.org

Contributors: JWL, LMV and MLN designed research protocol; YS and KB conducted dietary interventions; GDC and YS recruited participants; MNP's laboratory performed IGF-1 and IGBP-3 assays; MNP contributed data interpretation. SSR, JWL, MLN, CW, CYW analyzed the data; SSR, JWL and MLN wrote the paper and had primary responsibility for the final content. All authors were involved in the preparation of the final manuscript.
The study was registered at clinicaltrials.gov as NCT00622661.

syndrome.[13,14] The growth hormone-IGF axis is involved in carbohydrate metabolism;[15] however, dietary GL has not clearly been associated with IGF-I concentrations in epidemiological studies.[16] Some studies suggest, though evidence is limited, that higher insulin levels may indirectly increase bioavailability of circulating IGF-1.[17] Though few intervention studies have examined acute and chronic effects of GL on IGF-1 concentrations,[18–20] findings to date suggest a high-GL diet, possibly because of hyperinsulinemia, increases bioavailability of IGF-1.

We hypothesized that a high-GL diet would lead to lower circulating concentrations of IGF-1 and higher concentrations of IGFBP-3 compared with a low-GL diet. To address this hypothesis, we evaluated effects of 28-day, weight-maintaining, high-and low-GL controlled diets on circulating concentrations of fasting and post-prandial glucose, insulin, IGF-1 and IGFBP-3 and assessed modification of dietary effects by adiposity. We conducted a randomized, controlled crossover feeding trial in 84 normal weight (body mass index (BMI) = 18.5–24.9 kg/m^2) and overweight obese (BMI = 28.0–40.0 kg/m^2) healthy individuals.

SUBJECTS AND METHODS

Study population

We recruited healthy men and women from the local Seattle area by newspaper, flyer and Fred Hutchinson Cancer Research Center website announcements. Special efforts were undertaken to recruit African-American and Hispanic individuals at community and cultural events with high African-American or Hispanic attendance.[21] Inclusion criteria for the study were that participants (1) had no dietary restrictions, (2) had no physician-diagnosed conditions that might influence metabolic response to diet (for example, impaired glucose tolerance, diabetes, kidney, thyroid or cardiovascular disease), (3) had a BMI between 18.5 and 25.0 kg/m^2 or between 28.0 and 39.9 kg/m^2, (4) were not pregnant, lactating or considering pregnancy (5) were not using hormones or over-the-counter medications and (6) did not use tobacco or excessive alcohol (defined as two or more cans/bottles of beer, two or more glasses of wine or three or more ounces of hard liquor daily). We tested fasting blood glucose and excluded those with fasting glucose >5.55 mmol/l. We asked participants to discontinue use of all nutritional supplements before the feeding study. Participants completed baseline questionnaires to collect data on sex, race/ethnicity, health history, habitual diet and physical activity. The study protocol was approved by both the Institutional Review Board and Clinic Trials Office of the Fred Hutchinson Cancer Research Center, and all participants gave written informed consent.

Research design

We enrolled 89 participants in the study between June 2006 and July 2009 and block randomized participants by the BMI group (18.5–24.9 kg/m^2 or 28.0–40.0 kg/m^2) and sex to the order of experimental diets. In a crossover design, each participant consumed a high- or low-GL diet for 28 consecutive days during the first feeding period, followed by a 28-day wash-out period (during which participants consumed their habitual diet) and then consumed the other high- or low-GL diet for 28 days during the second feeding period. Study dietitians and staff prepared all foods and beverages for the dietary intervention periods in the Human Nutrition Laboratory (HNL) of the Fred Hutchinson Cancer Research Center and provided all food for the two feeding periods to the participants.[22] A subset of 20 participants completed post-prandial testing by consuming a test breakfast at the end of each feeding period.

We instructed participants to consume only the food and beverages provided by the HNL during the feeding periods, with the exception of tea and coffee (whitener and sweetener additives provided by study), which was permitted at stable continuous levels. During the week, participants ate a daily dinner meal at the HNL under supervision by study staff and ate breakfast, lunch, snack and weekend meals at home. Participants returned unconsumed food (which was weighed and recorded by the HNL) and recorded daily consumption of food provided by the study and any non-study food taken outside of the HNL.

Anthropometry

We measured baseline height, weight and waist and hip circumferences and assessed percentage body fat by whole-body dual-energy X-ray absorptiometry scanning, using a GE Lunar DPX-Pro densitometer (GE Healthcare, Milwaukee, WI, USA) before the start of the first intervention period. Study staff weighed participants three times per week.

Study diets

We designed both high- and low-GL diets to be weight-maintaining. We used 3-day dietary records and estimates of daily energy needs (calculated from the Mifflin equation[23]) to predict an individual's energy needs during the dietary intervention periods. We intended both diets to represent realistic high- and low-GL diets that were similar in daily macronutrient composition (15% energy from protein, 30% energy from fat and 55% energy from total carbohydrate) but differing by GL (GL $\geqslant$250, GI 78 and GL $\leqslant$125, GI 34 for high-GL and low-GL diets, respectively). We first created 7-day high- and low-GL reference diets of 2400 kcal/day (see Supplemental Table 1). We next generated variations on the reference diet by adding or subtracting 200-kcal increments in proportional serving sizes of all foods to achieve diets varying in energy content between 1600 and 3600 kcal. This approach met the estimated energy needs of all of our participants. As an example, a diet containing 3600 kcal/day had similar nutrient composition to the diet containing 1600 kcal/day, but differed in portion sizes by proportional increments. To maintain a participant's weight within 3% of baseline weight, we made dietary energy adjustments in 200-kcal increments, if necessary, during the diet intervention periods. Although keeping percent energy from carbohydrate similar in both diets, we varied carbohydrate quality across diets to achieve high- or low-GL meals, calculated as previously published[24] (GL = GI $\times$ total carbohydrate content per serving/100). We utilized reported glucose-referenced GI values (2002 International Glycemic Index Tables[25]) and consulted the University of Sydney database (http://www.glycemicindex.com). Food composition data were obtained from ProNutra: Metabolic Diet Study Management System (Viocare Technologies, Inc., Princeton, NJ, USA) and the Nutrition Data System for Research (version 2005, Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN, USA), peer-reviewed publications of food composition and food manufacturers. The high- and low-GL diets differed in fiber content (mean fiber content in the 2400-kcal reference diet was 24 and 49 g/day for high- and low-GL diets, respectively) because higher fiber content food is generally found in lower GI foods. Test breakfasts for the post-prandial studies were actual meals within the high- and low-GL 28-day intervention diet menus. The high-GL test meal contained high-GI buckwheat pancakes, pancake-sirup, butter, a fruit-flavored drink and milk. The low-GL test meal contained a low-GI oat and buckwheat groats pancake, agave sirup, butter, strawberries, tomato juice and milk.

Sample collection and analysis

Before and at the end of each completed 28-day diet period, we obtained blood from fasted participants (12-h fast). In an ancillary post-prandial study in a subset of participants ($n = 20$), we evaluated post-prandial responses to the test meal breakfasts, corresponding to the high- and low-GL diets of the preceding feeding period. After beginning the meal (time 0), we obtained post-prandial blood draws at time points 15, 30, 45, 60, 90, 120, 180 and 240 min after the meal. Blood was collected and processed according to a standard protocol and stored at $-80\,^{\circ}$C until analysis.

The assay for serum glucose was performed enzymatically at the Northwest Lipid Research Laboratories (University of Washington), using Roche reagents on a Roche Module P Chemistry autoanalyzer (Roche Diagnostics Inc., Indianapolis, IN, USA). The intra-assay coefficient of variation was 0.8%. The assay for serum insulin was performed at the Diabetes Endocrinology Research Center Immunoassay Core Laboratory (University of Washington), and quantified by a two site assay using a Tosoh 2000 auto-analyzer (Tosoh Biosciences Inc., South San Francisco, CA, USA). The intra-assay coefficient of variation was 4.4%. If insulin concentrations were below the detectable range of 2.0 μU/ml, the reported concentration was imputed as 1.0 μU/ml, the midpoint between 0 and 2.0 (μU/ml). The Pollak laboratory conducted the assays for IGF-1 and IGFBP-3 using assays from Diagnostic Systems, Ltd (Webster, TX, USA); they performed enzyme-linked immunosorbent assay measurements for these analytes using a single production lot of reagents, conducted in duplicate. Coefficient of variations were $<9\%$ for intra-assay variation.

Statistical analysis

We aimed to test the effect of a 28-day low- vs high-GL intervention on fasting serum concentrations and post-prandial responses of metabolic

biomarkers including glucose, insulin, IGF-1 and IGFBP-3, and to assess modification of dietary effects by adiposity. We used paired *t*-tests for diet component analysis and used linear mixed models for biomarker analyses. Biomarker values were transformed by the natural logarithm to improve the normality assumption of the linear models. The linear mixed model allowed us to account for any correlation of paired outcomes from the same participant. In the linear mixed model, diet treatment, diet sequence and diet period were fixed effects and participant was a random effect. We calculated least squared means and 95% confidence intervals for two-sided tests and considered *P*-values <0.05 to be statistically significant. We adjusted all models for age, sex, baseline biomarker concentrations, diet sequence and feeding period. For the post-prandial analyses, we calculated incremental area under the curve (iAUC) by trapezoidal method[26] (sum of integrated areas above baseline biomarker values). The iAUC analyses for IGF-1 and IGFBP-3 were performed by additionally subtracting baseline values because post-prandial values were predominantly suppressed below baseline. As an estimate of glucose-adjusted insulin response, we calculated the quotient of post-prandial 240 min iAUC of insulin divided by that for glucose (iAUC insulin/iAUC glucose).[27] Homeostasis model assessment for insulin resistance (HOMA-IR) was calculated by taking the product of the fasting insulin and glucose in mg/dl and dividing this by 405;[28] glucose values are presented in SI units (1 mg/dl = 0.0555 mmol/l). We performed *a priori* subgroup analyses within strata of body fat mass where dual-energy X-ray absorptiometry-measured body fat was classified as high for males with $\geqslant$25% body fat and females with $\geqslant$32% body fat.[29] We formally assessed for an interaction between diet and body fat by creating cross-product terms and inserting in the linear mixed models. Two participants had missing dual-energy X-ray absorptiometry data and so were assigned to the high body fat mass group based on BMI (30.8 and 40.2 kg/m^2). A sample size of 88 participants, calculated *a priori*, predicted detection of a $>$30% difference in biomarker concentrations with 80% power. We analyzed the data using SAS (version 9.1.2 SAS Institute, Cary, NC, USA).

RESULTS

Baseline characteristics of participants are shown in Table 1. In total, 89 individuals met screening criteria and consented to join the study, 84 participants started the first feeding study and 2 individuals dropped out of the study during the first feeding period. In all, 80 participants completed both feeding periods and 2 completed only one feeding period (one completed the high- and the other completed the low-GL diet). We included the 80 participants who completed both diet periods in the analysis.

Table 2 shows planned daily mean macronutrient content, dietary GI, dietary GL and distribution of percent energy for both high- and low-GL 2400-kcal reference diets. All diets at each energy level were similar to the reference diet shown. Analyses of self-reported food consumption records and post-meal leftover food weight records revealed the percent energy consumed was not significantly different between diets and adherence to the diets was $>98\pm4$%. Weight was maintained throughout both dietary periods and necessary energy adjustments did not differ significantly by diet type or feeding period (data not shown). Table 3 shows planned mean macronutrient content, GI, GL and distribution of percent energy for the high- and low-GL test breakfast from each 2400-kcal reference diet. Test breakfast consumption of protein (g), total carbohydrate (g) and energy (kcal) were statistically different ($P<0.05$) by paired *t*-tests during the high- and low-GL test breakfasts.

The overall dietary intervention effects on glucose, insulin HOMA-IR, IGF-1, IGFBP3 and IGF-1/IGFBP3 are shown in Table 4. Fasting serum glucose concentrations were similar between diet treatments in the lean group but not in the overweight/obese group; mean fasting glucose was 0.12 mmol/l higher following the low- compared with the high-GL diet. Fasting insulin concentrations were not different between treatments in the group overall or within body fat subgroups and similarly, there were no significant differences in HOMA-IR. The low-GL diet led to

Table 2. Mean energy and macronutrient content of 2400 kcal high- and low-GL reference diets[a]

	High-GL diet n = *7 days*	*Low-GL diet* n = *7 days*
Dietary descriptor	*Mean ± s.d.*	*Mean ± s.d.*
Energy (kcal/day)[b]	2398 ± 8	2396 ± 6
Protein (g/day)	90 ± 1	90 ± 0
Energy from protein (% using total carb)	15 ± 0.2*	14 ± 0.4*
Energy from protein (% using available carb)[c]	15 ± 0.2	16 ± 0.2
Fat (g/day)	80 ± 0	81 ± 1
Energy from fat (% using total carb)	30 ± 0.3*	29 ± 0.8*
Energy from fat (% using available carb)[c]	31 ± 0.2	31 ± 0.6
Total carbohydrate (g/day)	341 ± 6*	361 ± 15*
Energy from total carbohydrate (%)	56 ± 0.5*	57 ± 1.1*
Energy from available carbohydrate (%)[c]	54 ± 0.8	53 ± 0.8
Dietary fiber (g/day)	24 ± 5*	49 ± 8*
GI/day	78 ± 5*	34 ± 1*
GL load/day	244 ± 14*	117 ± 3*

Abbreviations: GI, glycemic index; GL, glycemic load. [a]Data from ProNutra: Metabolic Diet Study Management System (Viocare Technologies) and/or the Nutrition Data System for Research (version 2005, Nutrition Coordinating Center, University of Minnesota). [b]Total energy calculated as sums of 4 kcal/g protein, 9 kcal/g fat and 4 kcal/g total carbohydrate. [c]Total energy calculated using available carbohydrate. Asterisk (*) next to *P*-value <0.05 for paired *t*-tests comparing high- and low-GL diets.

Table 1. Baseline characteristics of 80 participants by gender and body fat status

Characteristic	*All*	*Male*	*Female*	*Low BF %*[a]			*High BF %*[a]		
				All	*Male*	*Female*	*All*	*Male*	*Female*
Sample (*n*)	80	40	40	29	16	13	51	24	27
Age (years)[b]	29.6 ± 8.2	31.0 ± 8.3	28.2 ± 7.9	28.6 ± 7.1	28.0 ± 7.3	29.2 ± 6.9	30.2 ± 8.8	33.0 ± 8.5	27.8 ± 8.4
Ethnicity									
Hispanic[c]	20 (25)	13	7	9	7	2	11	6	5
Caucasian[c]	35 (44)	16	19	12	4	8	23	12	11
Black[c]	16 (20)	6	10	2	1	1	14	5	9
Other[c]	9 (11)	5	4	6	4	2	3	1	2
Height (cm)[b]	171.4 ± 10.5	178.7 ± 7.4	164.1 ± 7.8	171.7 ± 10.8	179 ± 7.9	162.8 ± 6.0	171.2 ± 10.5	178.5 ± 7.3	164.8 ± 8.5
Weight (kg)[b]	81.1 ± 21.7	88.4 ± 21.9	73.9 ± 19.1	77.2 ± 21.5	81.1 ± 24.2	72.5 ± 17.5	83.4 ± 21.7	93.3 ± 19.2	74.5 ± 20.1
BMI (kg/m^2)[b]	27.4 ± 5.9	27.5 ± 5.9	27.3 ± 6.0	26.1 ± 6.1	25.1 ± 6.0	27.3 ± 6.1	28.2 ± 5.7	29.2 ± 5.3	27.3 ± 6.1
BMI range[d]	19.5–40.2	19.5–40.2	20.0–38.9	19.5–40.2	19.5–40.2	20.5–38.7	20.0–39.1	20.2–39.1	20.0–38.9
DXA % BF[b]	32.8 ± 11.9	31.2 ± 12.1	34.4 ± 11.6	21.2 ± 6.9	20.3 ± 7.5	22.3 ± 6.1	39.7 ± 8.2	38.9 ± 8.0	40.5 ± 8.5

Abbreviations: BF, body fat; BMI, body mass index; DXA, dual-energy X-ray absorptiometry. [a]Low BF $<$25% for males or $<$32% for females; High BF $\geqslant$25% for males or $\geqslant$32% for females. [b]Mean ± s.d. [c]Sample size (%). [d]Minimum–maximum.

Table 3. Description of test breakfast meal from the 2400-kcal high and low glycemic diets

Food	*Energy (kcal)*	*Protein (g)*	*Fat (g)*	*Total carb. (g)*	*Fiber (g)*	*GI food*	*% Carb. x GI*	*Carb. (g) x GI/ 100*
High GL test breakfast								
Reduced fat, 2% milk	122	8	5	11	0	30	5	3
Buckwheat pancake	160	6	2	31	2	92	38	28
Salted butter	108	0	12	0	0			
Lemon-line Gatorade powder	58	0	0	15	0	78	16	12
Pancake sirup	66	0	0	17	0	68	16	12
Totals	513	14	19	74	2	268	74	55
Percent total energy (%)[a]		10	33	57				
Percent total energy (%)[b]		11	33	56				
Low GL test breakfast								
Reduced fat, 2% milk	122	8	5	11	0	30	4	3
Oat and buckwheat groats pancake	168	9	5	23	3	48	13	11
Salted butter	72	0	8	0	0			
Frozen, unsweetened strawberries	49	1	0	13	3	40	6	5
Canned tomato juice	28	1	0	7	1	33	3	2
Light agave nectar	114	0	0	30	0	32	12	10
Sugar-free pancake sirup	14	0	0	4	0			
Totals	568	19	18	89	6	183	37	32
Percent total energy (%)[a]		13	27	60				
Percent total energy (%)[b]		13	29	58				

Abbreviations: Carb; carbohydrate; GI, glycemic index; GL, glycemic load; wt, weight; %, percent of meal carbohydrate. [a]Total energy calculated as sums of 4 kcal/g protein, 9 kcal/g fat and 4 kcal/g total carbohydrate. [b]Percent total energy calculated using available carbohydrate.

4% lower fasting concentrations of IGF-1 (10.6 ng/ml, $P = 0.04$) and a 4% lower ratio of IGF-1/IGFBP-3 (0.24, $P = 0.01$) compared with the high-GL diet. The effect of GL on IGF-1 concentration and ratio of IGF-1/IGFBP-3 within body fat subgroups did not reach statistical significance, except for a lower ratio of IGF-1/IGFBP-3 due to the low-GL diet in the high body fat subgroup. Body fat subgroups had similar fasting IGF-1 concentrations (interaction term for diet and adiposity $P = 0.8$). Diets resulted in no statistically significant difference between fasting concentrations of IGFBP3.

The post-prandial study results for 20 participants are shown in Table 4. Following a high- or low-GL test breakfast, the adjusted mean iAUCs for post-prandial glucose and insulin responses were significantly higher (both $P < 0.01$) following the high-GL breakfast compared with the low-GL breakfast. A difference in diet effect was nonsignificant for the ratio of iAUC insulin/iAUC glucose over 240 min. Concentrations of IGF-1 and IGFBP-3 changed very little between 0 and 240 min following the meals; however, there was a statistically significant decline ($\sim$4–5% below baseline concentrations) in mean IGF-1 concentrations from fasting during the first 60 min after both test meals (paired *t*-test for difference between mean concentrations at 60 min and at baseline $P < 0.01$). There was no significant decline from baseline at 60 min for the ratio of IGF-1/IGFBP-3. Figure 1 shows the mean concentrations of glucose, insulin, IGF-1 and IGFBP-3, beginning at time 0 before the meals and at all time-points following high-and low-GL test meals. The interaction term for diet and body fat category was not significant for fasting and integrated post-prandial concentrations of glucose, insulin, IGF-1, IGFBP-3 and ratio of IGF-1/IGFBP-3.

DISCUSSION

In this randomized controlled feeding study, the mean fasting IGF-1 concentration and ratio of IGF-1/IGFBP-3 were 4% lower following 28 days of the low-GL diet compared with the high-GL diet. The effect of GL on fasting ratio of IGF-1/IGBP-3 appeared strongest within the overweight obese stratum of adiposity, though adiposity was not a statistically significant modifier of dietary effect in these analyses. Higher circulating concentrations of IGF-I may be a risk factor for obesity-linked cancer.[30] Mechanistically, some propose diet-induced hyperinsulinemia leads to higher circulating bioactive IGF-1 concentrations by suppression of IGFBP-1,[17] and thus may be a causal link between carcinogenesis and these diets.[31] In this study, the clinical significance of the low-GL diet effects to moderately lower fasting IGF-1 concentration and ratio IGF-1/IGFBP-3, may be contributing factors in the lower cancer risk ascribed to low-GL diets in epidemiological studies.[8] Our observation, that the effect of a low-GL diet on IGF-1 concentration was especially strong in overweight obese participants, may be an important finding as these individuals are considered at even higher cancer risk.[10]

Aside from regulation by growth hormone, circulating concentrations of IGF-1 and IGFBP-3 are influenced by chronic nutritional status.[32–35] Studies of the chronic effects of GL on IGF-1 concentrations during periods of weight stability are limited. Although not testing GL, *per se*, two previous intervention studies showed no differences in fasting total IGF-1 or IGFBP-3 concentrations following 1 year of a prescribed low-fat, high-fiber diet when compared with 1 year or 4 years of a usual diet.[36,37] In an epidemiological study, total carbohydrate intake, fiber intake and GL were not associated with IGF-1 or IGFBP-3 concentrations.[16] Our finding of a modest effect of GL on IGF-1 concentration after only 28 days is novel and suggests GL may be another important chronic nutritional factor influencing the growth hormone IGF-1 axis.

Higher circulating concentrations of IGF-I have been associated with reduced risk of impaired glucose tolerance, type-2 diabetes[38] and other components of the metabolic syndrome,[11,13,14] although these relationships may not be linear.[39] In our study, the high-and low-GL diets led to similar estimates of insulin sensitivity (HOMA-IR) between diets after 28 days. This contrasts with some previous intervention study findings that showed a low-GL diet improved insulin sensitivity,[40] usually in the context of diabetes or diet-induced weight loss. Our participants were healthy at baseline and weight stable during the intervention periods, thus insulin sensitivity would be less likely to change

Table 4. Fasting and integrated post-prandial concentrations following 28-day high- or low-GL dietary interventions for all participants and within body fat subgroups[a,b]

	N	*High-GL*	*Low-GL*	*Difference*	P-*value*
Fasting measures[c]					
Glucose (mmol/l)	80	4.92 (4.86–4.98)	5.00 (4.94–5.06)	− 0.08	**0.04**
Low body fat	29	4.80 (4.70–4.90)	4.80 (4.70–4.90)	0.0	0.97
High body fat	53	5.00 (4.92–5.07)	5.12 (5.04–5.19)	− 0.12	**0.02**
Insulin (μU/ml)	80	8.3 (7.6–9.1)	8.2 (7.5–9.0)	0.2	0.73
Low body fat	29	5.9 (5.2–6.8)	5.6 (5.0–6.6)	0.2	0.62
High body fat	53	10.3 (9.2–11.6)	10.0 (8.9–11.2)	0.4	0.63
HOMA-IR	80	1.82 (1.66–2.01)	1.82 (1.66–2.01)	0.00	0.99
Low body fat	29	1.25 (1.08–1.46)	1.23 (1.06–1.43)	0.02	0.75
High body fat	53	2.29 (2.02–2.60)	2.27 (2.0–2.57)	0.03	0.88
IGF-1 (ng/ml)	80	281.5 (273.3–289.9)	270.9 (263.1–279.0)	10.6	**0.04**
Low body fat	29	276.7 (262.5–291.7)	268.7 (254.9– 283.2)	8.0	0.33
High body fat	53	277.9 (267.8–288.3)	267.4 (257.8–277.4)	10.4	0.12
IGFBP-3 (ng/ml)	80	4890 (4800– 4981)	4908 (4818–4999)	− 18	0.75
Low body fat	29	4770(4604– 4942)	4669 (4506–4838)	101	0.29
High body fat	53	4941 (4837–5046)	5028 (4922–5135)	− 87	0.21
IGF1/IGFBP-3	80	5.76 (5.62–5.90)	5.52 (5.39–5.66)	0.24	**0.01**
Low body fat	29	5.80 (5.60–6.01)	5.75 (5.55–5.96)	0.05	0.69
High body fat	53	5.62 (5.44–5.82)	5.32 (5.14–5.50)	0.31	**0.02**
Post-prandial measures[d]					
Glucose iAUC (mmol/l/240 min)	20	148.1 ± 25.4	83.9 ± 12.4	64.3 ± 21.8	< **0.01**
Low body fat	8	183.0 ± 30.2	123.7 ± 22.3	59.3 ± 34.2	0.08
High body fat	12	157.5 ± 29.5	83.3 ± 9.05	74.1 ± 24.9	< **0.01**
Insulin iAUC (μU/ml/240 min)	20	8417 ± 808	6164 ± 567	2253 ± 539	< **0.01**
Low body fat	8	9905 ± 1710	7622 ± 1402	2284 ± 749	< **0.01**
High body fat	12	8672 ± 698	6240 ± 355	2432 ± 685	< **0.01**
Insulin iAUC/glucose iAUC (pmol/mmol)	20	309.9 ± 131.5	169.4 ± 43.2	140.5 ± 145.9	0.34
Low body fat	8	317.1 ± 174.8	135.1 ± 73.9	183.8 ± 145.9	0.21
High body fat	12	272.1 ± 156.8	203.6 ± 59.5	68.5 ± 183.8	0.71
IGF-1 iAUC (ng/ml/240 min)[e]	20	− 2577 ± 514	− 2359 ± 685	− 218 ± 824	0.79
Low body fat	8	− 4271 ± 710	− 4370 ± 979	99 ± 1385	0.94
High body fat	12	− 2043 ± 695	− 1607 ± 794	− 437 ± 1020	0.69
IGFBP-3 iAUC (ng/ml/240 min)[e]	20	− 41162 ± 12282	− 19585 ± 13668	− 21577 ± 14980	0.15
Low body fat	8	− 90973 ± 16328	− 86212 ± 17185	− 4760 ± 17596	0.79
High body fat	12	− 24017 ± 13709	6861 ± 10717	− 30877 ± 19649	0.11

Abbreviations: GL, glycemic load; HOMA-IR, homeostasis model assessment for insulin resistance; iAUC, incremental area under the curve; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3. [a]Adjusted for design effects, age, gender and body fat percent. [b]Low body fat $<25\%$ for males or $<32\%$ for females; high body fat $\geqslant 25\%$ for males or $\geqslant 32\%$ for females. [c]Geometric means (CI). [d]Mean ± s.e.m. [e]Negative values for iAUC represent responses for which post-prandial concentrations were predominantly lower than fasting concentrations.

significantly over 28 days. There was a statistically significant but small (~0.06 mmol/l) higher mean fasting glucose following the low-GL diet; the clinical significance of this may be unimportant. Other studies typically show no change in fasting glucose or a lowering effect due to the low-GL diet.[40,41] One long-term intervention study found that the low-GL diet led to slightly higher mean fasting blood glucose;[42] the authors considered the implication of this finding to be minor. Findings for post-prandial effects of GL are more consistent across intervention studies.

High-GL meals, as compared with low-GL meals, reliably lead to higher post-prandial glucose and insulin concentrations in both healthy and insulin-resistant individuals.[43,44] Our results are consistent with those previous studies. When post-prandial insulin responses were adjusted for glucose responses (iAUC insulin/iAUC glucose), we did not detect a statistically significant difference between test breakfast types, suggesting β-cell function was not affected by the preceding 28-day GL diets. The effect of GL on β-cell function has varied in previous human and animal intervention studies.[45,46]

Our findings do not support an acute post-prandial effect of GL on post-prandial IGF-1 or IGBP-3 concentrations. Our IGF-1 findings are consistent with those of Brand-Miller *et al.*[18] who reported GI had minimal effect on post-prandial free and total IGF-1 concentrations.[18] Our findings are consistent with another study in which IGF-I concentration was relatively stable after an oral glucose tolerance test.[47] Circulating concentrations of IGF-1 are considered relatively insensitive to acute post-prandial changes[47] because of the stabilizing effect of IGFBP-3.[48] Perhaps unexpectedly, the high- and low-GL meals led to similar modest post-prandial declines in mean IGF-1 concentration at 60 min. On the other hand, neither meal affected concentrations of IGBP-3 in our study, in contrast to findings by Brand-Miller *et al.*[18] who observed divergent GI effects on IGFBP-3. The discrepancy between post-prandial IGFBP-3 responses in both studies might be explained by the large standard error of IGFBP-3 responses.

There are several strengths of this study. The crossover intervention utilized two controlled diets designed to match distribution of percent energy from macronutrients over



Figure 1. Mean (± s.e.m.) concentrations of (**a**) plasma glucose, (**b**) plasma insulin, (**c**) serum IGF-1 and (**d**) serum IGFBP-3 in 20 healthy lean and overweight obese participants, who were fasting (time 0) and then consumed a high- (dotted lines and closed squares) or low- (thin line and open squares) GL breakfast. The iAUC are significantly different for glucose and insulin and not significantly different for IGF-1 and IGFBP-3.

a single-day and 7-day cycle while maintaining an individual's weight throughout experimental dietary periods. The two diets were characterized by substantially different GLs and adherence to these diets was very high for both diets, thus ensuring appropriate exposure to high- and low-glycemic carbohydrate loads. We used typically consumed carbohydrate-containing foods with published, validated GI values. The parent study size of 80 participants was relatively large compared with most studies for which all food is provided and adherence is closely monitored. To our knowledge, this is the only study in healthy individuals examining the effects of weight maintaining high- and low-GL diets over several weeks followed by post-prandial testing of IGF-1 and IGFBP-3 on high- and low-GL background diets. There are several important limitations of our study. Mean dietary macronutrient and energy content differed slightly between the high- and low-GL test meals; small differences in mean macronutrient and energy intake between the two breakfasts may obscure an effect of GL. Diets were designed to be realistic and therefore fiber content was naturally higher in the low-GL 28-day diet and the test meal. Consequently, this study cannot distinguish effects of fiber from effects of GL. Post-prandial analyses within body fat subgroup may not have achieved statistical power to detect diet effects due to small sample sizes. Finally, participants for the post-prandial study were sampled by convenience, thereby possibly introducing selection bias. For these reasons, our post-prandial results may not be generalizable to all lean or overweight obese groups.

In conclusion, our findings show that consumption of a low-GL diet resulted in lower post-prandial insulin and glucose responses and modestly lower fasting IGF-1 and IGF-1/IGFBP-3 concentrations. There was no observable effect of GL on insulin resistance or glucose-adjusted post-prandial insulin responses in these healthy participants. Low-GL diets induce a metabolic profile that could decrease risk for some cancer types. Further intervention studies are needed to weigh the impact of dietary GL on risk for chronic disease.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

Solo Bars was provided by Solo GI Nutrition, Kewlona, British Columbia, Canada. Light Agave Nectar was provided by Madhava Natural Sweeteners, Longmont, CO, USA. This study is supported by the NIH grants U54 CA116847, R03 CA132158 and T32HL007028.

REFERENCES

1 Opperman AM, Venter CS, Oosthuizen W, Thompson RL, Vorster HH. Meta-analysis of the health effects of using the glycaemic index in meal-planning. *Br J Nutr* 2004; **92**: 367–381.
2 Pawlak DB, Ebbeling CB, Ludwig DS. Should obese patients be counselled to follow a low-glycaemic index diet? Yes. *Obes Rev* 2002; **3**: 235–243.
3 Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM *et al.* Glycemic index of foods: a physiological basis for carbohydrate exchange. *Am J Clin Nutr* 1981; **34**: 362–366.
4 Jenkins DJ, Kendall CW, Augustin LS, Franceschi S, Hamidi M, Marchie A *et al.* Glycemic index: overview of implications in health and disease. *Am J Clin Nutr* 2002; **76**: 266S–273S.
5 Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D, Jenkins DJ *et al.* Dietary fiber, glycemic load, and risk of NIDDM in men. *Diabetes Care* 1997; **20**: 545–550.
6 Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *JAMA* 1997; **277**: 472–477.
7 Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG *et al.* Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med* 2001; **345**: 790–797.
8 Gnagnarella P, Gandini S, La Vecchia C, Maisonneuve P. Glycemic index, glycemic load, and cancer risk: a meta-analysis. *Am J Clin Nutr* 2008; **87**: 1793–1801.
9 Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Glycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis. *Am J Clin Nutr* 2009; **89**: 568–576.
10 Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. *Nat Rev Cancer* 2004; **4**: 505–518.
11 Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. *Clin Endocrinol* 1994; **41**: 85–93.
12 Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *Lancet* 2004; **363**: 1346–1353.
13 Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Malarstig A, Brismar K *et al.* IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. *Clin Sci* 2009; **116**: 507–512.
14 Lam CS, Chen MH, Lacey SM, Yang Q, Sullivan LM, Xanthakis V *et al.* Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. *Arterioscler Thromb Vasc Biol* 2010; **30**: 1479–1484.

15 Clemmons DR. Role of insulin-like growth factor iin maintaining normal glucose homeostasis. *Horm Res* 2004; **62**(Suppl 1): 77–82.
16 Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. *Cancer Epidemiol Biomarkers Prev* 2002; **11**: 852–861.
17 Attia N, Tamborlane WV, Heptulla R, Maggs D, Grozman A, Sherwin RS *et al.* The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. *J Clin Endocrinol Metab* 1998; **83**: 1467–1471.
18 Brand-Miller JC, Liu V, Petocz P, Baxter RC. The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects. *Am J Clin Nutr* 2005; **82**: 350–354.
19 Smith R, Mann N, Makelainen H, Roper J, Braue A, Varigos G. A pilot study to determine the short-term effects of a low glycemic load diet on hormonal markers of acne: a nonrandomized, parallel, controlled feeding trial. *Mol Nutr Food Res* 2008; **52**: 718–726.
20 Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. *J Am Acad Dermatol* 2007; **57**: 247–256.
21 Coronado GD, Ondelacy S, Schwarz Y, Duggan C, Lampe JW, Neuhouser ML. Recruiting underrepresented groups into the carbohydrates and related biomarkers (CARB) cancer prevention feeding study. *Contemp Clin Trials* 2012; **33**: 641–646.
22 Neuhouser ML, Schwarz Y, Wang C, Breymeyer K, Coronado G, Wang CY *et al.* A low-glycemic load diet reduces serum C-reactive protein and modestly increases adiponectin in overweight and obese adults. *J Nutr* 2012; **142**: 369–374.
23 Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr* 1990; **51**: 241–247.
24 Brand-Miller JC, Thomas M, Swan V, Ahmad ZI, Petocz P, Colagiuri S. Physiological validation of the concept of glycemic load in lean young adults. *J Nutr* 2003; **133**: 2728–2732.
25 Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values 2002*Am J Clin Nutr* 2002; **76**: 5–56.
26 Wolever TM, Jenkins DJ. The use of the glycemic index in predicting the blood glucose response to mixed meals. *Am J Clin Nutr* 1986; **43**: 167–172.
27 Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ *et al.* Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. *Diabetes Care* 2009; **32**: 335–341.
28 Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding 'insulin resistance': both glucose resistance and insulin resistance are required to model human diabetes. *Metabolism* 1991; **40**: 908–917.
29 Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL *et al.* Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. *Am J Clin Nutr* 2009; **89**: 500–508.
30 Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. *Endocr Rev* 2007; **28**: 20–47.
31 Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. *J Nutr* 2001; **131**: 3109S–3120S.
32 Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB *et al.* Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. *Cancer Epidemiol Biomarkers Prev* 2003; **12**: 84–89.
33 Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. *J Clin Invest* 1983; **71**: 175–182.
34 Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. *Endocr Rev* 1994; **15**: 80–101.
35 McGreevy KM, Hoel BD, Lipsitz SR, Hoel DG. Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. *Public Health Nutr* 2007; **10**: 97–105.
36 Gann PH, Kazer R, Chatterton R, Gapstur S, Thedford K, Helenowski I *et al.* Sequential, randomized trial of a low-fat, high-fiber diet and soy supplementation: effects on circulating IGF-I and its binding proteins in premenopausal women. *Int J Cancer* 2005; **116**: 297–303.
37 Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Rosen CJ *et al.* The effects of a high-fruit and -vegetable, high-fiber, low-fat dietary intervention on serum concentrations of insulin, glucose, IGF-I and IGFBP-3. *Eur J Clin Nutr* 2008; **62**: 186–196.
38 Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. *Lancet* 2002; **359**: 1740–1745.
39 Brugts MP, van Duijn CM, Hofland LJ, Witteman JC. Lamberts SW, Janssen JA. Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. *Diabetes* 2010; **59**: 505–508.
40 Livesey G, Taylor R, Hulshof T, Howlett J. Glycemic response and health—a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. *Am J Clin Nutr* 2008; **87**: 258S–268S.
41 Vrolix R, Mensink RP. Effects of glycemic load on metabolic risk markers in subjects at increased risk of developing metabolic syndrome. *Am J Clin Nutr* 2010; **92**: 366–374.
42 Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG *et al.* The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. *Am J Clin Nutr* 2008; **87**: 114–125.
43 Lan-Pidhainy X, Wolever TM. Are the glycemic and insulinemic index values of carbohydrate foods similar in healthy control, hyperinsulinemic and type 2 diabetic patients? *Eur J Clin Nutr* 2011; **65**: 727–734.
44 Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care* 2003; **26**: 2261–2267.
45 Andersson U, Rosen L, Wierup N, Ostman E, Bjorck I, Holm C. A low glycaemic diet improves oral glucose tolerance but has no effect on beta-cell function in C57BL/6J mice. *Diabetes Obes Metab* 2010; **12**: 976–982.
46 Solomon TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M *et al.* A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. *Am J Clin Nutr* 2010; **92**: 1359–1368.
47 Frystyk J, Grofte T, Skjaerbaek C, Orskov H. The effect of oral glucose on serum free insulin-like growth factor-I and -II in health adults. *J Clin Endocrinol Metab* 1997; **82**: 3124–3127.
48 Murphy LJ. The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. *Exp Diabesity Res* 2003; **4**: 213–224.